Deutsche Bank Cuts Kos Pharmaceuticals to 'Hold'

Analyst David Steinberg cites a rapid deceleration in prescription growth for Niaspan

Deutsche Bank downgraded Kos Pharmaceuticals (KOSP ) to hold, from buy.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.